In a deeper examination of the tumor tissue, we observed a considerable decrease in the mRNA expression levels of PSA and KLK2 - known target genes of AR - in response to the combined therapy of YIV-818-A and enzalutamide (Figures 5C, D). This evidence concerns the gene KLK2 and neoplasm.